Trial Profile
Prospective study of anti-HCV therapy with pan-genotype direct acting anti-viral agents for patients with chronic liver diseases
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Jul 2022
Price :
$35
*
At a glance
- Drugs Glecaprevir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 01 Jul 2022 Planned End Date changed from 31 Dec 2022 to 21 Jan 2022.
- 17 Dec 2018 New trial record
- 13 Nov 2018 Results (n=123; data cut off: 10 May, 2018) presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases